Details for Patent: 12,133,844

« Back to Dashboard

Which drugs does patent 12,133,844 protect, and when does it expire?

Patent 12,133,844 protects FYARRO and is included in one NDA.

This patent has fifty patent family members in twenty-seven countries.

Summary for Patent: 12,133,844

Title:	Methods of treating epithelioid cell tumors
Abstract:	The present invention provides methods and compositions for treating epithelioid cell tumors (such as a PEComa) by administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin.
Inventor(s):	Neil P. Desai
Assignee:	Abraxis Bioscience LLC
Application Number:	US17/165,652
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 12,133,844

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG/M2 OR 56 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
Aadi	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE

International Family Members for US Patent 12,133,844

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016285720
Australia	2021286245
Brazil	112017027954
Canada	2990693